Meningococcal Vaccines Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Meningococcal Vaccines market is Segmented by Type (Polysaccharide Vaccines, Conjugate Vaccines, Combination Vaccines, and Others), End-user and Geography

Market Snapshot

Meningococcal Vaccines Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.5 %
Meningococcal Vaccines Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the meningococcal vaccines market include the increase in public-private partnerships to support the development of vaccines at low cost, and rising immunization programs and government initiatives.

The rising prevalence of meningitis is expected to increase the demand for meningitis vaccine resulting in high growth of the market. Meningitis can be caused by many different pathogens but the highest global burden is seen with bacterial meningitis. As per the data published by the National Meningitis Association (NMA), in the United States, approximately 600-1,000 people contract the meningococcal disease each year. Furthermore, 21% of the meningococcal disease cases occur in preteens, teens, and young adults. Thus, rising cases of meningitis are expected to create huge demand for meningitis vaccines. 

Also, there is a rising public-private partnership to support the development of vaccines and create awareness among the population. Hence, the Meningococcal Vaccines market is expected to witness high growth over the forecast period.

Scope of the Report

As per the scope of this report, the meningococcal meningitis is a rare but potentially devastating bacterial infection that targets the brain. Despite growing advances in medical care, the disease can kill the host within a relatively lesser time span. The meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitis and there are various types of vaccines available in the market. 

By Type
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
Others
By End User
Hospitals
Pharmacy Stores
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Polysaccharide Vaccine is expected to hold Largest Market Share over the Forecast Period

Internationally marketed meningococcal polysaccharide vaccines are bivalent (A and C), trivalent (A, C, and W-135) or tetravalent (A, C, Y, and W-135). The vaccines are purified, heat-stable, lyophilized capsular polysaccharides from meningococci of the respective serogroups. The vaccines have been helpful in curbing the exponential growth of the disease, and are expected to do so in the future as well. This is expected to help the market growth.

The polysaccharide vaccines continue to witness high traction from developing countries due to limited supply by few vaccine manufacturers, market forerunners are collaborating with local distributors to expand their footprint. 

Meningococcal Vaccines Market Key Trends

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest meningococcal vaccine market owing to the rising awareness of the disease and the presence of better healthcare infrastructure. The rates of meningococcal disease declining in the United States since the 1990s. As per the data published by the Center for Disease Control and Prevention (CDC), in 2017 there were approximately 350 total cases of meningococcal disease reported. Furthermore, there is a rising awareness among the population. 

In the United States, the Meningitis Foundation of America (MFA) is a non-profit organization dedicated to providing information and support to individuals who have had personal experience with meningitis. Also, this foundation is to create awareness in the public and the medical communities about the initial symptoms of meningitis. Thus, owing to the all above-mentioned factors the Meningococcal Vaccines market is expected to witness steady growth over the forecast period.

Meningococcal Vaccines Market Growth Rate

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. Some of the market players are Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Pasteur Inc., and Serum Institute of India Ltd.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in Public-Private Partnerships to Support Development of Vaccines at Low Cost

      2. 4.2.2 Rising Immunization Programs and Government Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost associated with Storage and Supply of Vaccines

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Polysaccharide Vaccines

      2. 5.1.2 Conjugate Vaccines

      3. 5.1.3 Combination Vaccines

      4. 5.1.4 Others

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Pharmacy Stores

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bio-Manguinhos

      2. 6.1.2 Biomed Pvt. Ltd

      3. 6.1.3 GlaxoSmithKline plc

      4. 6.1.4 Merck & Co., Inc.

      5. 6.1.5 Novartis AG

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Sanofi Pasteur Inc.

      8. 6.1.8 Serum Institute of India Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Meningococcal Vaccines Market market is studied from 2018 - 2026.

The Meningococcal Vaccines Market is growing at a CAGR of 9.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Poonawalla Investments & Industries Pvt. Ltd. (Serum Institute of India Ltd.) are the major companies operating in Meningococcal Vaccines Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!